Loading
A phase 2 trial of YL202 should be intravenously infused in non-small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Study of YL202 in Selected Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06107686 by MediLink Therapeutics (Suzhou) Co., Ltd., with 200 participants planned, started 2023-12-15 and due to reach its primary completion in 2026-11. Interventions recorded: YL202 should be intravenously infused.
Shares YL202, MediLink Therapeutics and the tag pipeline.
Shares MediLink Therapeutics and the tag pipeline.
Shares YL202, MediLink Therapeutics, Non-small-cell lung cancer.
Shares MediLink Therapeutics and the tag pipeline.
Shares MediLink Therapeutics and the tag pipeline.
Shares YL202, MediLink Therapeutics.
Shares MediLink Therapeutics and the tag pipeline.
Shares YL202, MediLink Therapeutics, Non-small-cell lung cancer.